Status of Radiolabeled Monoclonal Antibodies for Diagnosis and Therapy of Cancer
June 01, 1996
Almost exactly one decade ago, in an editorial published in the New England Journal of Medicine , I noted that "progress is slow but sure" in the development of monoclonal antibodies for clinical use. At that time, only muromonab-CD3 (Orthoclone OKT3) was approved for human use to prevent rejection of kidney transplants. In the ensuing 10 years, only one oncologic monoclonal antibody product, satumomoab pendetide (OncoScint CR/OV, Cytogen, Princeton, New Jersey)  has been approved by the FDA. Progress surely has been slow.